Clovis Oncology Investor Relations Material
Latest events
Q2 2022
Clovis Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Clovis Oncology Inc
Access all reports
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company's clinical trial programs comprise three drug candidates designed to inhibit the growth of cancer tumors. Its lead product candidate is NDA 20-538 for metastatic adenocarcinoma of the pancreas; and other preclinical assets include NK-1 receptor antagonists for the treatment of inflammatory bowel disease; glio-selectins for the treatment of glioblastoma multiforme; and JTK inhibitors for multiple indications. Clovis Oncology markets its products through a limited direct sales force in the majority of its markets. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
CLVS
Country
🇺🇸 United States